{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:52:55Z","timestamp":1792720375078,"version":"4.5.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are autoimmune disorders characterized by inflammatory episodes affecting the brain and the gastrointestinal (GI) tract, respectively. The frequent association between MS and IBD suggests that both conditions may share common pathogenic mechanisms. However, different responses to biological therapies indicate differences in immune mechanisms of inflammation. Anti-CD20 therapies are high efficacy treatments increasingly used to control inflammatory bursts in MS, but they may alter GI homeostasis and promote the development of bowel inflammation in susceptible individuals. This review analyzes the mechanistic association between immunity in MS and IBD, the effect of anti-CD20 therapies on the gut microenvironment, and provides recommendations for early detection and management of GI toxicities in the context of B-cell depletion in MS patients.<\/jats:p>","DOI":"10.3389\/fphar.2023.1186016","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:00:56Z","timestamp":1685466056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review"],"prefix":"10.3389","volume":"14","author":[{"given":"A.","family":"Quesada-Sim\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garrido-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Nos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gil-Perot\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/ecco-jcc\/jjab073.118","article-title":"DOP79 primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER multicenter case series","volume":"15","author":"Albshesh","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","article-title":"Severe ulcerative colitis after rituximab therapy","volume":"126","author":"Ardelean","year":"2010","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ibneur.2021.08.003","article-title":"The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis","volume":"11","author":"Asha","year":"2021","journal-title":"IBRO Neurosci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.12998\/wjcc.v10.i8.2569","article-title":"Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn\u2019s disease: A case report and review of literature","volume":"10","author":"Au","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"B5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: Interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.20524\/aog.2021.0582","article-title":"Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis","volume":"34","author":"Barnes","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.gastrohep.2018.05.003","article-title":"Rituximab-associated colitis","volume":"42","author":"Barreiro Alonso","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1002\/ibd.22963","article-title":"Rituximab-associated colitis","volume":"19","author":"Bhalme","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1200\/JCO.2010.31.8899","article-title":"Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma","volume":"29","author":"Blombery","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s13311-017-0582-3","article-title":"Intestinal permeability in relapsing-remitting multiple sclerosis","volume":"15","author":"Buscarinu","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awy131","article-title":"The intestinal barrier in multiple sclerosis: Implications for pathophysiology and therapeutics","volume":"141","author":"Camara-Lemarroy","year":"2018","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4143\/crt.2020.406","article-title":"Crohn\u2019s disease following rituximab treatment for follicular lymphoma in a patient with synchronous gastric signet ring cells carcinoma: A case report and literature review","volume":"52","author":"Cavalcanti","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.4049\/jimmunol.170.4.1707","article-title":"B cell developmental requirement for the G \u03b1 i2 gene","volume":"170","author":"Dalwadi","year":"2003","journal-title":"J. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S678","DOI":"10.1093\/ecco-jcc\/jjx107","article-title":"Targeting S1P in inflammatory bowel disease: New avenues for modulating intestinal leukocyte migration","volume":"12","author":"Danese","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/apt.12997","article-title":"Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: Retrospective analysis of 9095 patients","volume":"41","author":"de Felice","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"108916","DOI":"10.1016\/j.clim.2021.108916","article-title":"Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects","volume":"234","author":"del Sordo","year":"2022","journal-title":"Clin. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gut.2006.103564","article-title":"Risks and benefits of biologic therapy for inflammatory bowel diseases","volume":"56","author":"D\u2019Haens","year":"2007","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cgh.2019.03.027","article-title":"De novo colitis associated with rituximab in 21 patients at a tertiary center","volume":"18","author":"Eckmann","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.3275\/7411","article-title":"Systemic adverse events following rituximab therapy in patients with Graves\u2019 disease","volume":"34","author":"el Fassi","year":"2011","journal-title":"J. Endocrinol. Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/gut.2007.138305","article-title":"Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves\u2019 disease","volume":"57","author":"el Fassi","year":"2008","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: A single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3899\/jrheum.160456","article-title":"Perianal Crohn disease after treatment with rituximab for active granulomatosis with polyangiitis","volume":"43","author":"Fraser","year":"2016","journal-title":"J. Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":"Exacerbation of ulcerative colitis after rituximab salvage therapy","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-Cell therapy for multiple sclerosis: Entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: A review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 optimum study: A randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e220033","DOI":"10.1148\/rycan.220033","article-title":"Ulcerative colitis exacerbation after rituximab treatment in posttransplant lymphoproliferative disease","volume":"4","author":"Klug","year":"2022","journal-title":"Radiol. Imaging Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ajcp\/aqab133","article-title":"Histologic findings and tissue B-cell depletion in endoscopic mucosal biopsy specimens of the gastrointestinal tract after treatment with rituximab","volume":"157","author":"Kmeid","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/00365521.2020.1854847","article-title":"Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018","volume":"56","author":"Kristj\u00e1nsson","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.gastrohep.2020.07.020","article-title":"Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis","volume":"44","author":"Ladr\u00f3n Abia","year":"2021","journal-title":"Gastroenterol. Hepatol. (English Ed."},{"key":"B36","doi-asserted-by":"publisher","first-page":"8858378","DOI":"10.1155\/2020\/8858378","article-title":"Ocrelizumab-induced severe colitis","volume":"2020","author":"Lee","year":"2020","journal-title":"Case Rep. Gastrointest. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut"},{"key":"B38","first-page":"58","article-title":"Fulminant colitis following rituximab therapy","volume":"12","author":"Lipka","year":"2016","journal-title":"Gastroenterol. Hepatol. (NY)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737175.9.3.319","article-title":"Why did IL-12\/IL-23 antibody therapy fail in multiple sclerosis?","volume":"9","author":"Longbrake","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/COC.0000000000000553","article-title":"Clinical features of rituximab-associated gastrointestinal toxicities","volume":"42","author":"Mallepally","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e252140","DOI":"10.1136\/bcr-2022-252140","article-title":"Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis","volume":"15","author":"Malloy","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: Current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1172\/JCI36030","article-title":"Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression","volume":"118","author":"Matsushita","year":"2008","journal-title":"J. Clin. Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/intimm\/12.5.597","article-title":"Regulatory role of mature B cells in a murine model of inflammatory bowel disease","volume":"12","author":"Mizoguchi","year":"2000","journal-title":"Int. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13730-018-0364-8","article-title":"Crohn\u2019s disease following rituximab treatment in a patient with refractory nephrotic syndrome","volume":"8","author":"Morita","year":"2019","journal-title":"Cen. Case Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.23238","article-title":"B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-\u03b2 receptor II dominant negative mice","volume":"50","author":"Moritoki","year":"2009","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1080\/14712598.2017.1366444","article-title":"Natalizumab in the treatment of Crohn\u2019s disease patients","volume":"23","author":"Pagnini","year":"2017","journal-title":"Expert Opin. Biol. Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/ibd.21242","article-title":"Case series: Ulcerative colitis, multiple sclerosis, and interferon-beta 1a","volume":"16","author":"Rodrigues","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.3390\/ijms22147618","article-title":"Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease","volume":"22","author":"Saez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: Results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pharma.2011.06.005","article-title":"Ulcerative colitis: Exceptional consequence after rituximab therapy","volume":"69","author":"Sekkach","year":"2011","journal-title":"Ann. Pharm. Fr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.msard.2018.02.030","article-title":"A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review","volume":"22","author":"Shahmohammadi","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/ibd\/izz270","article-title":"Treatment of rituximab-induced Crohn\u2019s disease with ustekinumab induction and long-term maintenance of remission","volume":"26","author":"Shankar","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/ibd\/izaa057","article-title":"First case of refractory colitis caused by ocrelizumab","volume":"26","author":"Sunjaya","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2169\/internalmedicine.5119-20","article-title":"Rituximab-induced ileocolitis in a patient with gastric MALToma: A case report and literature review","volume":"60","author":"Tsuzuki","year":"2021","journal-title":"Intern Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13577","article-title":"Efficient long-term depletion of CD20 + B cells by rituximab does not affect gut-resident plasma cells","volume":"1415","author":"Uzzan","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","article-title":"Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE","volume":"122","author":"Vallerskog","year":"2007","journal-title":"Clin. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3899\/jrheum.100818","article-title":"Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis","volume":"38","author":"Vallet","year":"2011","journal-title":"J. Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00365521.2017.1280530","article-title":"Rituximab-induced Crohn\u2019s disease","volume":"52","author":"Varma","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.51495","article-title":"Multiple sclerosis and inflammatory bowel disease: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbadis.2010.06.009","article-title":"The role of antibodies in multiple sclerosis","volume":"1812","author":"Weber","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"B65","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/400_2009_21","article-title":"Cooperation of B Cells and T Cells in the pathogenesis of multiple sclerosis","volume":"51","author":"Weber","year":"2009","journal-title":"Results Probl. Cell Differ."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1073\/pnas.0409449102","article-title":"Mesenteric B cells centrally inhibit CD4 + T cell colitis through interaction with regulatory T cell subsets","volume":"102","author":"Wei","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3748\/wjg.v20.i12.3255","article-title":"Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease","volume":"20","author":"Xu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1038\/s41467-021-25768-0","article-title":"Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"645500","DOI":"10.3389\/fmicb.2021.645500","article-title":"Lactobacillus reuteri alleviates gastrointestinal toxicity of rituximab by regulating the proinflammatory T cells in vivo","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"174","DOI":"10.14740\/gr1041w","article-title":"Anti-inflammatory biologics and anti-tumoral immune therapies-associated colitis: A focused review of literature","volume":"11","author":"Zhou","year":"2018","journal-title":"Gastroenterol. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.crohns.2009.10.005","article-title":"Neurologic manifestations in inflammatory bowel diseases: Current knowledge and novel insights","volume":"4","author":"Zois","year":"2010","journal-title":"J. Crohns Colitis"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1186016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:01:01Z","timestamp":1685466061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1186016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":72,"alternative-id":["10.3389\/fphar.2023.1186016"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1186016","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1186016"}}